{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:12:38Z","timestamp":1792642358828,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcyt.2024.03.009","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T09:15:07Z","timestamp":1710580507000},"page":"778-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products"],"prefix":"10.1016","volume":"26","author":[{"given":"Mark D.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Better","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Jazayeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Yohrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jadlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Goessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"McKelvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Pilon-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary S.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Veldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Vong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P.","family":"Weinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.03.009_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0002","unstructured":"H.R.2617 - 117th Congress (2021-2022): Consolidated Appropriations Act, 2023. (2022). Retrieved from https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617. Accessed May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0003","unstructured":"FDA. Considerations for the development of chimeric antigen receptor (CAR) T cell products; draft guidance for industry. Retrieved from http:\/\/www.regulations.gov. Accessed May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0004","unstructured":"FDA. Human gene therapy products incorporating human genome editing; draft guidance for industry. Retrieved from http:\/\/www.regulations.gov. Accessed May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0005","unstructured":"FDA. Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial; guidance for industry. Retrieved from https:\/\/www.fda.gov\/media\/106369\/download. (2022). Accessed May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0006","unstructured":"FDA. Q9(R1) quality risk management guidance for industry ICH-quality. Retrieved from https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-regulatory-information-biologics\/biologics-guidance. Accessed May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0007","unstructured":"FDA. Chemistry, manufacturing, and controls changes to an approved application: certain biological products; guidance for industry. Retrieved from https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-regulatory-information. (2021). Accessed May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0008","unstructured":"FDA. Manufacturing changes and comparability for human cellular and gene therapy products; draft guidance for industry. Retrieved from https:\/\/www.fda.gov\/media\/170198\/download. Accessed July 28, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0009","unstructured":"FDA. Interpreting sameness of gene therapy products under the orphan drug regulations; guidance for industry. https:\/\/www.fda.gov\/media\/113760\/download. (2021). Accessed on May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0010","doi-asserted-by":"crossref","first-page":"CT219","DOI":"10.1158\/1538-7445.AM2021-CT219","article-title":"Abstract CT219: master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer","volume":"81","author":"Schoenfeld","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0011","unstructured":"YESCARTA (axicabtagene ciloleucel). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel (2022). Accessed on May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0012","unstructured":"TECARTUS (brexucabtagene autoleucel).https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel (2022). Accessed on May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0013","unstructured":"FDA. Approved Risk Evaluation and Mitigation Strategies (REMS). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=IndvRemsDetails.page&REMS=375 (2022). Accessed on Moay 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0014","unstructured":"International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use Pharmaceutical Development Q8(R2). (2009).https:\/\/www.ema.europa.eu\/en\/ich-q8-r2-pharmaceutical-development-scientific-guideline. Accessed on May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0015","unstructured":"International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use Ich Harmonised Guideline Quality Risk Management Q9(R1). https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf. Accessed on May 13, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1479-5876-8-26","article-title":"An integrative paradigm to impart quality to correlative science","volume":"8","author":"Kalos","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0017","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cyto.b.21985","article-title":"Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses","volume":"100","author":"Sarikonda","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0018","unstructured":"FDA. Comparability Protocols for human drugs and biologics: chemistry, manufacturing, and controls information guidance for industry. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm. Accessed on May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/hgtb.2016.120","article-title":"A rapid cell expansion process for production of engineered autologous CAR-T cell therapies","volume":"27","author":"Lu","year":"2016","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0020","unstructured":"FDA. Long term follow-up after administration of human gene therapy products; guidance for industry 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-. Accessed on May 14, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0022","unstructured":"FDA. Formal meetings between the FDA and sponsors or applicants of PDUFA products guidance for industry DRAFT GUIDANCE. https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-regulatory-information-biologics\/biologics-. Accessed on May 13, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0023","unstructured":"FDA. Interactions with office of therapeutic products.https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/interactions-office-therapeutic-products (2023). Accessed on July 17, 2023."},{"key":"10.1016\/j.jcyt.2024.03.009_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s43441-021-00258-z","article-title":"Expedited Development programs at the food and drug administration: insights and opportunities","volume":"55","author":"Collins","year":"2021","journal-title":"Ther Innov Regulat Sci"},{"key":"10.1016\/j.jcyt.2024.03.009_bib0025","unstructured":"Friends of Cancer Research. The next generation of cellular therapies: a blueprint to accelerate development. https:\/\/friendsofcancerresearch.org\/event\/the-next-generation-of-cellular-therapies-a-blueprint-to-accelerate-development\/ (2023). Accessed on August 12, 2023."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T13:58:05Z","timestamp":1720879085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924000975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1465324924000975"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.009","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}